Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
Michael Teufel , Karl Köchert , Gerold Meinhardt , Jordi Bruix
Background: REG is a multikinase inhibitor which improved overall survival (OS; HR 0.63, 95% CI 0.50, 0.79; P<0.0001) and time to progression (TTP; HR 0.44, 95% CI 0.36, 0.55; P<0.0001) compared with placebo in patients with HCC who progressed during prior sorafenib treatment in the RESORCE trial. This exploratory analysis evaluated the impact of baseline AFP and c-Met on REG treatment benefit (OS and TTP) in the RESORCE trial. Methods: Circulating AFP and c-Met protein (shed ectodomain) levels were quantified by a Luminex assay (Myriad RBM) in plasma samples collected at baseline from patients enrolled in the RESORCE trial. Valid biomarker data were available from 497 (AFP) and 499 (c-Met) out of 573 patients. Patients were subgrouped according to the median protein concentration (high vs low), and the treatment effect HR and its 95% CI were evaluated using a Cox proportional hazards model. The predictive effect was modeledas a protein–treatment interaction effect and subjected to Akaike information criterion (AIC)-based selection to assess its association with OS and TTP. Results: Baseline characteristics of patients were balanced across protein subgroups. While increased levels of both AFP (HR 1.09, 95% CI 1.07, 1.12; P<0.001) and c-Met (HR 1.32, CI 95% 1.06, 1.63; P=0.011) were associated with a worse prognosis for OS, increased AFP levels were also associated with poor prognosis for TTP (HR 1.05, 95% CI 1.03, 1.07; P<0.001). REG treatment benefit for both OS and TTP was independent of AFP and c-Met protein expression (Table). The protein–treatment interaction effect was not statistically significant. Conclusions: The treatment benefit of REG in patients with HCC was independent of AFP and c-MET protein expression at baseline. So far, no single protein has been associated with REG clinical benefit. Clinical trial information: NCT01774344
Protein, expression | OS HR (95% CI) | OS P-value | TTP HR (95% CI) | TTP P-value |
---|---|---|---|---|
AFP, low | 0.62 (0.44, 0.87) | 0.006 | 0.39 (0.28, 0.52) | <0.001 |
AFP, high | 0.58 (0.42, 0.79) | <0.001 | 0.46 (0.34, 0.62) | <0.001 |
c-Met, low | 0.55 (0.39, 0.76) | <0.001 | 0.37 (0.27, 0.50) | <0.001 |
c-Met, high | 0.65 (0.47, 0.90) | <0.01 | 0.48 (0.36, 0.65) | <0.001 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2019 Gastrointestinal Cancers Symposium
First Author: Robin Kate Kelley
2022 ASCO Annual Meeting
First Author: Guoliang Shao
2018 Gastrointestinal Cancers Symposium
First Author: Jordi Bruix
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Laura A. Dawson